TY - JOUR
T1 - Fatigue Symptoms During the First Year Following ARDS
AU - Neufeld, Karin J.
AU - Leoutsakos, Jeannie Marie S.
AU - Yan, Haijuan
AU - Lin, Shihong
AU - Zabinski, Jeffrey S.
AU - Dinglas, Victor D.
AU - Hosey, Megan M.
AU - Parker, Ann M.
AU - Hopkins, Ramona O.
AU - Needham, Dale M.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: K. J. N. has received research grant funds from Hitachi Corporation for the study of Near Infra-red spectroscopy in delirium; and has been a consultant to Merck & Co. None declared (J.-M. S. L., H. Y., S. L., J. S. Z., V. D. D., M. M. H., A. M. P., R. O. H., D. M. N.).
Funding Information:
FUNDING/SUPPORT: This research was supported by the National Heart, Lung, and Blood Institute [Grants R24 HL111895 , R01HL091760 , and R01HL091760-02S1 ], the Johns Hopkins Institute for Clinical and Translational Research [Grant UL1 TR 000424-06 ], and the Albuterol for Treatment of Acute Lung Injury Trial (ALTA), Early Versus Delayed Enteral Nutrition Trial (EDEN), Omega Nutrition Supplement Trial (OMEGA), and Statins for Acutely Injured Lungs from Sepsis Trial (SAILS) [ National Heart, Lung, and Blood Institute contracts HHSN268200536165C to HHSN268200536176C and HHSN268200536179C ].
Publisher Copyright:
© 2020 American College of Chest Physicians
PY - 2020/9
Y1 - 2020/9
N2 - Background: Fatigue is commonly reported by ARDS survivors, but empirical data are scarce. Research Question: This study evaluated fatigue prevalence and associated variables in a prospective study of ARDS survivors. Study Design and Methods: This analysis is part of the ARDSNet Long-Term Outcomes Study (ALTOS) conducted at 38 US hospitals. Using age- and sex-adjusted, time-averaged random effects regression models, we evaluated associations between the validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale with patient and critical illness variables, and with physical, cognitive, and mental health status at 6 and 12 months following ARDS. Results: Among ARDS survivors, 501 of 711 (70%) and 436 of 659 (66%) reported clinically significant symptoms of fatigue at 6 and 12 months, respectively, with 41% and 28% reporting clinically important improvement and worsening (n = 638). At 6 months, the prevalence of fatigue (70%) was greater than that of impaired physical functioning (50%), anxiety (42%), and depression (36%); 46% reported both impaired physical function and fatigue, and 27% reported co-existing anxiety, depression, and fatigue. Fatigue was less severe in men and in those employed prior to ARDS. Critical illness variables (eg, illness severity, length of stay) had little association with fatigue symptoms. Worse physical, cognitive, and mental health symptoms were associated with greater fatigue at both the 6- and 12-month follow-up. Interpretation: During the first year following ARDS, more than two-thirds of survivors reported clinically significant fatigue symptoms. Due to frequent co-occurrence, clinicians should evaluate and manage survivors’ physical, cognitive, and mental health status when fatigue is endorsed.
AB - Background: Fatigue is commonly reported by ARDS survivors, but empirical data are scarce. Research Question: This study evaluated fatigue prevalence and associated variables in a prospective study of ARDS survivors. Study Design and Methods: This analysis is part of the ARDSNet Long-Term Outcomes Study (ALTOS) conducted at 38 US hospitals. Using age- and sex-adjusted, time-averaged random effects regression models, we evaluated associations between the validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale with patient and critical illness variables, and with physical, cognitive, and mental health status at 6 and 12 months following ARDS. Results: Among ARDS survivors, 501 of 711 (70%) and 436 of 659 (66%) reported clinically significant symptoms of fatigue at 6 and 12 months, respectively, with 41% and 28% reporting clinically important improvement and worsening (n = 638). At 6 months, the prevalence of fatigue (70%) was greater than that of impaired physical functioning (50%), anxiety (42%), and depression (36%); 46% reported both impaired physical function and fatigue, and 27% reported co-existing anxiety, depression, and fatigue. Fatigue was less severe in men and in those employed prior to ARDS. Critical illness variables (eg, illness severity, length of stay) had little association with fatigue symptoms. Worse physical, cognitive, and mental health symptoms were associated with greater fatigue at both the 6- and 12-month follow-up. Interpretation: During the first year following ARDS, more than two-thirds of survivors reported clinically significant fatigue symptoms. Due to frequent co-occurrence, clinicians should evaluate and manage survivors’ physical, cognitive, and mental health status when fatigue is endorsed.
KW - acute lung injury
KW - cognitive function
KW - depression
KW - disability
KW - rehabilitation
UR - http://www.scopus.com/inward/record.url?scp=85085311076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085311076&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2020.03.059
DO - 10.1016/j.chest.2020.03.059
M3 - Article
C2 - 32304774
AN - SCOPUS:85085311076
VL - 158
SP - 999
EP - 1007
JO - Diseases of the chest
JF - Diseases of the chest
SN - 0012-3692
IS - 3
ER -